NeoGenomics Q2 revenue beats estimates, raises outlook
NEO•Drivers of the quarter
- NGS growth — The company said 26% year-over-year growth in next-generation sequencing revenue contributed to the overall revenue increase.
- Higher pricing — Average revenue per clinical test rose 12% to $515, supporting revenue growth.
- Cost discipline — Operating expenses fell 19%, mainly due to the absence of prior-year impairment charges.
Full-year 2026 outlook raised
The company raised full-year 2026 revenue guidance to $802 million-$806 million.
NeoGenomics also increased full-year 2026 adjusted EBITDA guidance to $56 million-$58 million.
It expects full-year 2026 GAAP net loss of $42 million-$34 million.
Q2 revenue and EPS beat estimates
NeoGenomics said second-quarter revenue rose 11% year over year, beating analyst expectations.
Adjusted EPS for the quarter also beat consensus.
